Breast cancer is the most prevalent cancer in women that frequently spreads and recurs, thus leading to high mortality. Despite advances in surgery and treatment, standard of care still relies primarily on chemo- and radiation therapies aimed at killing the tumor cells. Evolutionary models predict that selective pressure imposed by these approaches causes survival of resistant clones that eventually re-activate the disease. Based on the central involvement of metabolic tumor cell alterations in cancer, this application follows the hypothesis that therapeutic normalization of tumor cell metabolism can halt breast cancer progression and prevent relapse. If successful, this approach would not eradicate all residual disease, but rather achieve and maintain a disease symptom-free state. In principle, treatment aimed at normalizing tumor cell metabolism would not impose selective pressure, and thus not favor penetration of escaping clones to drive recurrence. If successful, therapeutic metabolic reprogramming could become a critical component of breast cancer care and have revolutionary impact on overall outcome by reducing the mortality in breast cancer. Having identified a cause-and-effect relationship between aberrant tumor cell mitochondrial complex I function, oncogenic growth, and metastatic progression in breast cancer, this information translated into a new strategy, where normalization of the NAD+/NADH redox balance through treatment with NAD precursors led to inhibition of tumor growth and metastatic disease in xenograft models and interference with breast cancer progression in an oncogene driven transgenic model of spontaneous breast cancer. Based on these findings, the proposed study seeks to 1. Evaluate the efficacy of NAD precursor treatment in xenograft and transgenic mouse models of breast cancer progression, including combination with standard of care;2. Employ targeted metabolomics to define the tumor cell NAD+/NADH metabolome in defined stages of disease advancement and treatment using ESI QQQ and NIMS technology, combined with XCMS metabolomic bioinformatics;and 3. Generate untargeted comprehensive metabolic profiles of progressive stages in breast cancer. The outcome from our study may identify therapeutic normalization of tumor cell metabolism, e.g. through NAD precursor treatment, as an effective, non-toxic way to silence breast cancer and prevent recurrence. The metabolome of breast cancer progression will empower the field and enable development of preventive approaches based on the concept of metabolic normalization. Interactive and collaborative efforts using the information generated will help to reduce the mortality in breast cancer patients.
This project addresses NCIs provocative question PQ21: Given the appearance of resistance in response to cell killing therapies, can we extend survival by using approaches that keep tumors static? Despite improvements in breast cancer surgery and treatment, the mortality of breast cancer patients has largely remained unchanged. A major underlying problem is that the disease frequently recurs, often years after initial adjuvant therapy was apparently successful. At present, the standard of care relies primarily on chemo- and radiation therapies aimed at eradicating rapidly dividing tumor cells. However these treatments are very likely to select more aggressive tumor cells that eventually re-activate the disease and are treatment resistant. Dormant or slowly dividing tumor cells with stem-like characteristics could also remain unaffected and lead to recurrence. We hypothesize that breast cancer cells, regardless of the initial transforming event and disease driving mechanism, rely on altered metabolic circuitry that allows the tumor cells to meet their energy needs not only for accelerated growth, but also for survival under changing access to nutrients and oxygen within niches of the tumor microenvironment. Based on our result and the central involvement of metabolic tumor cell alterations in disease progression, we predict that therapeutic normalization of the tumor cell metabolism can halt breast cancer progression and prevent relapse. If successful, this approach would not eradicate all residual disease, but rather achieve and maintain a clinical disease symptom-free state. In principle, treatment aimed at normalizing tumor cell metabolism would not impose selective pressure and thus not favor penetration of escaping clones or cancer stem cells that could drive recurrence. Therefore, therapeutic metabolic reprogramming could become a critical component of breast cancer care and have revolutionary impact on overall outcome by reducing the mortality in breast cancer.
|Kularatne, Sumith A; Deshmukh, Vishal; Ma, Jennifer et al. (2014) A CXCR4-targeted site-specific antibody-drug conjugate. Angew Chem Int Ed Engl 53:11863-7|
|Johnson, Caroline H; Fisher, Timothy S; Hoang, Linh T et al. (2014) Luciferase does not Alter Metabolism in Cancer Cells. Metabolomics 10:354-360|
|Patti, Gary J; Tautenhahn, Ralf; Johannsen, Darcy et al. (2014) Meta-analysis of global metabolomic data identifies metabolites associated with life-span extension. Metabolomics 10:737-743|
|Rinehart, Duane; Johnson, Caroline H; Nguyen, Thomas et al. (2014) Metabolomic data streaming for biology-dependent data acquisition. Nat Biotechnol 32:524-7|
|Santidrian, Antonio F; LeBoeuf, Sarah E; Wold, Erik D et al. (2014) Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer. DNA Repair (Amst) 23:79-87|
|Gowda, Harsha; Ivanisevic, Julijana; Johnson, Caroline H et al. (2014) Interactive XCMS Online: simplifying advanced metabolomic data processing and subsequent statistical analyses. Anal Chem 86:6931-9|
|Sarkisyan, Gor; Gay, Laurie J; Nguyen, Nhan et al. (2014) Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth. Am J Physiol Cell Physiol 307:C14-24|
|Zhu, Zheng-Jiang; Schultz, Andrew W; Wang, Junhua et al. (2013) Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database. Nat Protoc 8:451-60|
|Ivanisevic, Julijana; Zhu, Zheng-Jiang; Plate, Lars et al. (2013) Toward 'omic scale metabolite profiling: a dual separation-mass spectrometry approach for coverage of lipid and central carbon metabolism. Anal Chem 85:6876-84|
|Patti, Gary J; Tautenhahn, Ralf; Rinehart, Duane et al. (2013) A view from above: cloud plots to visualize global metabolomic data. Anal Chem 85:798-804|
Showing the most recent 10 out of 11 publications